Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Doxycycline for Injection USP, 100 mg per vial and 200 mg per vial (Single-Dose Vial). The drug is a broad spectrum antibiotic and is indicated to treat or prevent a variety of infectious disorders that are proven or strongly suspected to be caused by susceptible bacteria.
It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
